AIM gains approval for trial of Ampligen for pancreatic cancer

AIM ImmunoTech has gained Netherlands Erasmus Medical Center (Erasmus MC) Ethics Committee authorisation to launch a European site for its Phase II clinical trial of Ampligen (rintatolimod) for locally advanced pancreatic cancer.